NASDAQ:PLRX Pliant Therapeutics Q1 2026 Earnings Report $1.22 -0.04 (-3.49%) As of 10:18 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pliant Therapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.36Beat/MissBeat by +$0.04One Year Ago EPSN/APliant Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APliant Therapeutics Announcement DetailsQuarterQ1 2026Date5/11/2026TimeBefore Market OpensConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETUpcoming EarningsPliant Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Pliant Therapeutics Earnings HeadlinesPliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 22, 2026 | seekingalpha.comPliant Therapeutics Announces Enrollment in Phase 1b Trial of PLN-101095 for ICI-Refractory Solid Tumors at ASCO 2026May 21, 2026 | quiverquant.comQBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 1 at 1:00 AM | Weiss Ratings (Ad)Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual MeetingMay 21, 2026 | globenewswire.comPliant Therapeutics Stock Short Interest Report | NASDAQ:PLRX | BenzingaMay 17, 2026 | benzinga.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 11, 2026 | finance.yahoo.comSee More Pliant Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pliant Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pliant Therapeutics and other key companies, straight to your email. Email Address About Pliant TherapeuticsPliant Therapeutics (NASDAQ:PLRX) (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems. The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). In preclinical studies, Pliant has also advanced research-stage integrin modulators aimed at addressing fibrosis in diabetic nephropathy and other indications with high unmet medical need. Founded in 2015, Pliant has built its research and development capabilities around translational biomarkers and validated preclinical models. The company’s clinical programs are conducted through multi‐center studies in North America, with plans to expand patient enrollment into additional geographies as part of global development efforts. Leadership at Pliant is led by President and Chief Executive Officer Vikram Shembekar, who brings extensive biopharmaceutical development experience. The management team combines expertise in clinical development, regulatory strategy and commercialization planning, positioning the company to advance its integrin-targeted pipeline toward potential regulatory approvals and eventual patient access.View Pliant Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysBest Buy’s AI Laptop Boost Sparks Hope for a BBY TurnaroundDollar Tree Keeps Winning After Family Dollar Divorce Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
